Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07240675
PHASE1

Single-dose,First-in-human of KLA478

Sponsor: Hunan Kelun Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single doses of KLA478 in healthy volunteers;

Official title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of KLA478 in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-11-26

Completion Date

2026-09-30

Last Updated

2026-02-27

Healthy Volunteers

Yes

Interventions

DRUG

pramipexole hydrochloride sustained-release tablets

P.O., single dose

DRUG

KLA478

intramuscular injection, single dose

DRUG

placebo

intramuscular injection, single dose

Locations (1)

Huashan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China